Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin + Lenalidomide in R/R MALT Lymphoma
NCT03031483Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Apr 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and clarithromycin in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Tumor response assessment. Started Apr 2017; status: completed.
02
Drugs
lenalidomideclarithromycin
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT03031483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031483.